#6 - Eli Lilly (NYSE:LLY)
An effective treatment for Alzheimer’s disease remains elusive but Eli Lilly (NYSE: LLY) received a breakthrough therapy designation from the FDA in 2021 for its leading Alzheimer’s drug candidate, Donanemab, which is designed to reduce the buildup of beta-amyloid plaque.
The company expects to hear back from the FDA early in 2023. If the FDA gives the company the go-ahead, Eli Lilly may accelerate its timing for bringing Donanemab to market and LLY stock will likely get a bounce on the news as well.
But that’s just one reason to consider LLY stock. The company has many commercially available drugs including its diabetes drug, Mounjaro, which just received FDA approval in October 2022. Eli Lilly continues to add to its treatment pipeline for cancer, immunology, diabetes, pain and neurodegeneration.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More - Current Price
- $767.76
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 17 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $1,002.22 (30.5% Upside)
